Page last updated: 2024-09-05

deferasirox and Hematologic Malignancies

deferasirox has been researched along with Hematologic Malignancies in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hikota, R; Horiuchi, T; Kato, S; Kimura, F; Kobayashi, A; Kobayashi, S; Maekawa, T; Osawa, Y; Sato, K; Watanabe, J; Yamamura, T1
Maekawa, T; Yoshioka, S1

Other Studies

2 other study(ies) available for deferasirox and Hematologic Malignancies

ArticleYear
Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.
    International journal of hematology, 2014, Volume: 100, Issue:3

    Topics: Benzoates; Blood Proteins; Deferasirox; Drug Monitoring; Female; Ferritins; Hematologic Neoplasms; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Multivariate Analysis; Prognosis; Protein Binding; Retrospective Studies; ROC Curve; Transfusion Reaction; Treatment Outcome; Triazoles

2014
[Transfusion reaction and HLA antibodies].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2

    Topics: Acute Lung Injury; Antibody Formation; Benzoates; Blood Transfusion; Deferasirox; Hematologic Neoplasms; Hemochromatosis; HLA Antigens; Humans; Iron Chelating Agents; Isoantibodies; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles

2012